Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2021-03-25
Target enrollment:
Participant gender:
Summary
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for
2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body
surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20%
BSA (excluding scalp).
The objectives of this study are to evaluate the exposure and characterize the plasma
pharmacokinetic profile and to assess the safety and tolerability of ARQ-151 cream 0.3%
administered once daily for 2 weeks to adolescent and adult subjects with chronic plaque
psoriasis.